---
document_datetime: 2023-09-21 18:53:39
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/mabthera-h-c-165-a20-78-epar-assessment-report-article-20_en.pdf
document_name: mabthera-h-c-165-a20-78-epar-assessment-report-article-20_en.pdf
version: success
processing_time: 21.4448587
conversion_datetime: 2025-12-15 01:12:30.09549
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

03 August 2012 EMA/488088/2013 CommitteeforMedicinal ProductsforHuman Use(CHMP)

## Assessmentreport

## MabThera

Rituximab

ProcedureNo.:EMEA/H/C/165/A-20/0078

## Note

AssessmentreportasadoptedbytheCHMPwithallinformationofacommerciallyconfidentialnature deleted.

Telephone+44(0)2074188400Facsimile+44(0)2074188416

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

1. Background information on the procedure.

2.Scientific discussion ..

2.1. Quality aspects ..

2.1.1.Root cause..

2.1.2.Corrective actions..

2.1.3. Inspection ..

2.2. Clinical aspects ..

2.2.1. Clinical safety...

2.3.Productinformation

3. Overall discussion and benefit/risk assessment.

4. Overall conclusion.

5. Conclusion and grounds for the recommendation.

4

4

4

5

5

5

6

6

<div style=\"page-break-after: always\"></div>

## 1.Backgroundinformationon theprocedure

TheEuropeanMedicinesAgencyandtheEuropeanCommissionwereinformedbythemarketing authorisationholder(MAH)ofMabTheraabouttheunexpectedpresenceofLeptospiralicerasiaein seed-trainbioreactorsusedfortheproductionoftheactivesubstance,rituximab，atitsGenentech (USA).Leptospiralicerasiaewasonlydetectedatpre-harvestphase(averyearlystageof manufacturing)bymicroscopicvisualexaminationandallculturesconfirmed tobecontaminatedwere discarded.Afurtherin-depthanalysisofthematterwasdeemednecessarytoevaluatetheimpactof thequalityissuesidentifiedinthemanufacturingofrituximabonthequalityandsafetyofthefinished product.

InviewoftheabovetheEuropeanCommissioninitiatedaprocedureunderArticle20ofRegulation s themarketingauthorisationforthisproductshouldbemaintained,varied，suspendedorwithdrawn.

## 2.Scientificdiscussion

MabThera(rituximab),authorisedsince 2June 1998,is agenetically engineeredchimeric mouse/humanmonoclonalantibodyindicatedforuseinadultsfornon-Hodgkin'slymphoma,chronic lymphocyticleukaemia(CLL)andrheumatoid arthritis².

InMay2011,thepresenceof Leptospiralicerasiae(alsoreferred toasLeptospirainthisdocument) bioreactorsattheVacaville(vv)site.Theorganismhadneverbeendetectedbeforeinthe Roche/GenentechbiologicalproductionnetworkanditwasidentifiedasLeptospiralicerasiaeby16S DNAsequencing.Theonlyindicationofcontaminationwasmicroscopicvisualexamination.Allpreharvestculturesconfirmedtobecontaminatedwerediscarded.Theinvestigationatthetime consideredthisanisolatedevent,however,inAugust2011，asecondcontaminationofthesame harvestculturesconfirmedtobecontaminatedwerediscarded.Asamplewiththeorganismwas successfullyculturedallowingadditionalstudiestounderstandrootcauseandpotentialadditional detectioncontrols.Drugsubstancelotswerenotvisuallycontaminated,butallthoselinked through genealogytothecontaminatedcultureswerenotusedbutconsideredforfurtherinvestigations.

InDecember2011 theCommitteeforMedicinalProductsforHumanUse(CHMP)wasinformedof the issuesobservedattheVacavillesite.Leptospiralicerasiaehadbeendetectedatpre-harveststagebut thedrugsubstancebatchesproduceddidnotconfirmthepresenceof Leptospirabymicroscopicvisual examinationandallculturesconfirmedtobecontaminatedwerediscarded.Downstreamin-process controlsandcertificatesofanalysismetacceptancecriteriaandspecificconditionssuchaslowpHand the downstreamprocessing aimed toprovide a robust clearance ofprocess-related impurities and potential processcontaminants.However,a furtherin-depth analysisof thematterwas deemed necessarytoevaluatetheimpactofthequalityissuesidentifiedinthemanufacturingofrituximabon thequalityandsafetyofthefinishedproduct.

TheMAHprovidedrelevantinformationontherootcauseevaluationandpreventionoffuture Leptospiraproblems,and thesewereconsideredintheframeworkof thisreview.Aninspectionwas heldattheVacavillesiteinFebruary2012,anditsresultswerealsotakenintoaccount.Asummaryof therelevantdataforthisreviewispresentedhereinafter.

1 Two sites are currently approved for the manufacture of MabThera's active substance (rituximab), Genentech Vacaville andGenentechOceanside,bothlocatedintheUnitedStatesofAmerica(UsA).

2For thefullindicationpleaserefer to theproduct informationwhich canbefound on theEPARfor MabThera.

<div style=\"page-break-after: always\"></div>

## 2.1.Qualityaspects

## 2.1.1.Rootcause

FurthertotheeventsattheVacavillesite，amethodologicalinvestigationintotherootcauseofthe utilisedtoevaluatepossiblecausesofthecontaminationdetectedatpre-harvestlevel.Investigations processes; cell banks used in Vacaville; breaches in the cooling tower water; personnel; antifoam; pest and autoclaving;carbonate(added tomedia);and thewaterforinjection(WFI)system.

Basedonalldataprovided,themostlikelycauseofthepresenceofLeptospiralicerasiaewasthe area.Acombinationofpersonnel(asexternalcarriers)and/ortheseoperationsinopenplasticvessels wasconsideredtohavecreatedaplausiblepathwayfortheorganismtobeintroducedintothemedia. SpirochetesfromtheLeptospiracaefamilywerealsoobservedintheenvironmentexternaltothe Vacavillefacility Irrigation water). wasanuntreatedopenwatersourcethat wasintermittentlyusedasmake-upwatertothecoolingtower;itsusehasnowbeenofficially discontinued.Otherpossiblerootcauseswereconsidered，suchasthecontaminationofrituximab's likelihoodofthesebeingcontaminatedwasconsideredverylow.

## 2.1.2.Correctiveactions

BasedonthecombinationoffactorswhichledtothefindingsofLeptospiralicerasiaeattheVacaville productionsiteatpre-harvestlevel,considerationsweregiventotheexistingprocesses,including downstreamelimination，andanyneedforimprovementsinthemanufacturingprocess.

equipmentsanitationprocedureswasevaluated.

The rituximabpurificationprocessproviderobustclearanceofa broadspectrumofprocessrelated impuritiesandprocesscontaminantswithvariablebiochemicaland physicalcharacteristics.Thedemonstratedabilitytoclear impuritiestoacceptablelevelsprovidesassurancethat LeptospiraandLeptospira-derivedcontaminantswouldlikelyberemovedfromtherituximabproduct. Leptospirawasdetecteddownstreamofthefilterwhenchallenged,inasmallscalestudy,with approximately 4.62 x 108 to 4.95 × 108 Leptospira/cm2 of filter surface area, demonstrating robust removalofLeptospira.Furthermore,basedonthedataprovided,theexistingregenerationand

additionalriskassessmentwasperformedtoevaluatetheadequacyofcurrentmicrobialcontrol systemsindrugsubstanceproductionforpreventingmicrobialcontaminationandevaluatethecurrent detectionandcontaminationresponseprocedure.Interimcorrectiveandpreventive actions(CAPA) wereinitiatedtopreventcontaminationatpre-harvestleveland，ifcontaminationoccurs,ensureits detection.Measuresincludedeliminationoftheuseofplasticcontainersinthepreparationofsmall cellculturefluidsamplesforallCHO-derivedproductssharingthesamemediacomponentsorcell sourceasrituximab;PCRtestingonpre-harvestcellculturefluidsamples(freshorfrozen)forallCHO derivedproductssharingthesamemediacomponentsorcellsourceasrituximab;andEMJHmedium

<div style=\"page-break-after: always\"></div>

culturemethodtestingonresidualfluidfromeachrituximabWorkingCellBank(WCB)ampoule followingeachthawoperation.

TheCHMPconsideredthattheproposedenhancementswereadequateinpreventingtheoccurrenceof futureLeptospiracontaminations.Inaddition,themeasuresinplacewillensurethedetectionof Leptospira,ifacontaminationwouldre-occur.Aperiodofmonitoringandassessmentofthemeasures inplaceisforeseen,andreportsareexpected tobesubmittedbytheMAH latestbyJanuary2013. During thisperiod,theinterimCAPAwillcontinue.If anychangesordiscontinuationof theagreed interimmeasuresimplementedatthesiteisenvisaged,thisshallbeimmediatelyreportedtotheCHMP validated.ItscompletionisexpectedbyendDecember2012.

Allchanges toprocesses,frequencies orlimits(e.g.specifications)resultingfrom the evaluationat the

## 2.1.3.Inspection

TheCHMPrequestedtheinspectionoftheactivesubstancemanufacturingsitelocatedinVacaville, 9February2012.Theinspectioninvolvedathoroughassessmentoflaboratories,warehousesaswell asmanufacturing and utilityfacilities.The inspectors also evaluated thequalitymanagementsystems atthesite.Theinspectorsconsideredthatoveralltherootcauseinvestigationconductedwassolidand thesitehadgoodunderstandingofGMP,andrulesweregenerallyfollowed.Afewminorissueswere reportedatthesite;thesewillbefollowedbytheinspectorateforcompletenessbutbarenoconcern for this review.

## 2.2.clinicalaspects

## 2.2.1. Clinical safety

outermembraneorenvelopesurroundsthecell.Itcontainsproteinssuchaslipopolysaccharide otherproteinssuchasexotoxins(hemolysins)havebeenidentified ascandidatevirulencefactors whichmaycontributetoLeptospirainfectionanddisease.

Basedontheavailabledata,noviableLeptospiraweredetectedatdrugsubstanceorfinishedproduct levels.The assessment of rituximab'spurificationprocess capacityforremovalofavarietyofproteins inactivateLeptospira.Rabbitpyrogentestresultswerealsoprovidedshowingthatalltestedfinished batches derived frompre-harvest cell culture which tested PCR-positive(i.e.,drug product batches whichwereprocessed fromLeptospira containingpre-harvestcellculture,butwhichwerenotused).

ThedetectionofLeptospiralicerasiaeatpre-harvestlevelhasbeenaddressedbyintroductionof interimcorrectiveandpreventiveactions(seealsosection2.1.2above),andallpre-harvestcultures considered tobe contaminated were discarded(will notbefurther processed).Althoughit is noted that pre-harvestmediawhichtestedpositivetoLeptospiralicerasiaewillnotbeusedforproduction,the

Itwasconcluded thatthetreatmentwithrituximabfinishedproductfromdrugsubstancebatches producedatVacavillewasnotassociatedwithclinicallyrelevantrisksforpatients.

<div style=\"page-break-after: always\"></div>

## 2.3.Productinformation

Therewerenochangestotheproductinformation.

## 3.Overalldiscussionandbenefit/riskassessment

MabThera(rituximab),authorisedsince2June1998,isageneticallyengineeredchimeric mouse/humanmonoclonal antibodyindicated foruse in adultsfornon-Hodgkin's lymphoma,chronic lymphocyticleukaemia(CLL)andrheumatoidarthritis3.

In May 2011, the presence of Leptospira licerasiae was detected at very early stages of manufacturing sitelocatedinVacaville，UnitedStatesofAmerica.Theonlyindicationofcontaminationwas microscopicvisual examination.Allpre-harvestcultures confirmed tobe contaminatedwere discarded. Theinvestigationatthetimeconsideredthisanisolatedeventhowever,inAugust2011，asecond inonebioreactor.Allpre-harvestculturesconfirmedtobecontaminatedwerediscarded.Asamplewith theorganismwassuccessfullyculturedallowingadditionalstudiestounderstandrootcauseand potentialadditionaldetectioncontrols.Drugsubstancelotswerenotvisuallycontaminated,butall those linked through genealogy to the contaminated cultures were not used but considered forfurther investigations. transmittedfromanimalstohumans.However，basedontheinvestigationstheCHMPconsideredthat treatmentwithrituximabfinishedproductfromdrugsubstancebatchesproducedatVacavillewasnot associatedwithclinicallyrelevantrisksforpatients.

Leptospiraweredetectedatdrugsubstanceorfinishedproductlevels.Furthermore,evenifcultures whereLeptospiraorLeptospira-derivedcontaminantspresentatpre-harvestlevelhadbeenused,the currentrituximabpurificationprocessforproteins andprocess-related impuritiessupported that the wouldalsobeexpectedtoinactivateanyLeptospira.

Regardingthequalityinvestigations,andbasedonallavailablequalitydata，includinginformationfrom aninspectionheldattheVacavillesite,themostlikelyrootcauseforthecontaminationofthe rituximabseedtrainbioreactorswithLeptospiralicerasiaewasthemediapreparationoperationsinthe SmallVolumeMediaPreparation(SVMP)area.Acombinationofpersonnel(asexternalcarriers)and/or operationsinopenplasticvesselswasconsideredtohavecreatedaplausiblepathwayfortheorganism tobeintroducedintothemedia.TheCHMPconcludedthatbatchesofdrugsubstancelinkedtocultures whichtestedpositiveatpre-harvestwillnotbefurtherprocessedandinterimcorrectiveandpreventive thedetectionofLeptospira.Themeasuresincludedeliminationoftheuseofplasticcontainersinthe preparationofsmallvolumecellculturemediaandreplacementwithanexistingstainlesssteelmedia tank;theuseofHighTemperatureShortTime(HTST)treatmentofcellculturemediatodifferent culturemethodtestingonnon-frozenpre-harvestcellculturefluidsamplesforallCHO-derived productssharing thesamemediacomponentsorcellsourceasrituximab;PCR(polymerasechain reaction)testing of LeptospiraDNAonpre-harvestcellculturefluid samples(freshorfrozen)for all CHOderivedproductssharingthesamemediacomponentsorcellsourceasrituximab;andEMJH mediumculturemethodtestingonresidualfluidfromeachrituximabWorkingCellBank(WCB) ampoule.

TheCHMPconsidered thattheproposed measureswere adequateinpreventingtheoccurrenceof futureLeptospiracontaminations.Inaddition,themeasuresinplacewillensurethedetection of Lepstopira，ifacontaminationwouldre-occur.Aperiodofmonitoringandassessmentofthemeasures inplaceisforeseen,andreportsareexpectedtobesubmittedbythemarketingauthorisationholder ordiscontinuationisenvisaged,thisshallbeimmediatelyreportedtotheCHMPforassessment.A

3 For the fullindication please refer to the product information which can be found on the EPAR for Mabthera.

<div style=\"page-break-after: always\"></div>

moresensitivePCRmethodisalsobeingdevelopedbytheMAHandwillneed tobevalidated.Its completionisexpectedbyendof2012.

## Benefit/riskbalance

Inviewof theabove,theCommitteeconsidersthatthebenefitriskbalanceofMabThera(rituximab)is

## 4.Overallconclusion

HavingconsideredthedataprovidedbytheMAHsinwritingandintheoralexplanations，and the informationavailablefromtheinspectionoftheaffectedsite，theCHMPconcludedthatthedataare sufficienttoconcludeontheLeptospirafindings atthemanufacturingsitelocatedinVacaville,USA.

ThereforetheCHMPrecommendedthemaintenanceofthemarketingauthorisationsubjectedtothe followingconditions:

(i) The MAH shall not use any drug substance batch manufactured from Leptospira PCR positive preharvests;

(ii)TheMAHshallsubmitallon-goingCAPAassessmentsbyendJanuary2013;

(ili)TheMAHshalldevelopandvalidateamoresensitivePCRmethodofdetectionof Leptospiraand submititsreportbyend2012;

(iv)TheMAHshall submit the appropriatevariations if changes toprocesses,frequencies or limits resultingfromtheevaluationatthesitearetobeimplemented.

normalconditionsofuse,subjecttoagreedconditions.

## 5.Conclusionandgroundsfor therecommendation

- TheCommitteeconsidered theprocedureunderArticle20ofRegulation(EC)No726/2004,for MabThera initiated by the European Commission;
- TheCommitteereviewedallavailabledataprovidedbytheMAHorallyandinwritingregarding thedetectionofLeptospiralicerasiaeatveryearlystagesofmanufacturing(pre-harvest)ofthe activesubstanceatasitelocatedinVacaville,USA;theCommitteeconsideredalsothe informationavailablefromtherequestedinspectionofthesite,heldinFebruary2012;
- TheCommitteeconsidered thatthemostlikelyrootcauseofthecontaminationhasbeen identified as the media preparation operations in the Small Volume MediaPreparation(SVMP) area.AdequatecorrectiveandpreventivemeasureswereintroducedattheVacavillesiteto minimiseanypotentialcontaminationandmaximisethedetectionofLeptospira;
- TheCommitteeconcluded thatthefindingsarenotassociatedwithanyclinicallyrelevantrisk positiveforLeptospirawillnotbefurtherprocessed,andnobacteriaweredetectedatdrug substance orfinishedproductlevels.Inaddition,the CHMPconsidered that therobustness of the manufacturingprocess should ensureremoval of any Leptospira or Leptospira-derived contaminants;
- TheCommitteeconcludedthatthebenefit-riskbalanceofMabTheraispositiveundernormal conditionsofuse,subjecttotheconditionsagreed.

TheCHMPhasthereforerecommended themaintenanceofthemarketingauthorisation,subjecttothe conditionslaiddowninAnnexIIoftheopinion.